Agios Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
Check the end of the webpage for potential risks for Agios Pharmaceuticals Inc based on industry, geography and size. The ESG rating for Agios Pharmaceuticals Inc indicates the company's reporting of the UN SDGs. The ESG score includes seventeen UN Sustainable Development Goals including: 'Quality Education', 'Industry, Innovation & Infrastructure' and 'Partnerships for the Goals'.
Agios Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 4.6, social score of 5.0 and governance score of 5.0.
5.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 912 | Vivanza Biosciences Ltd | 5.3 | High |
| 912 | ValiRx PLC | 5.3 | High |
| 958 | Agios Pharmaceuticals Inc | 5.2 | High |
| 958 | Altimmune Inc | 5.2 | High |
| 958 | Alliance Pharma PLC | 5.2 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Agios Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc report the average age of the workforce?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc offer flexible work?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc conduct supply chain audits?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Agios Pharmaceuticals Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose water use targets?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Agios Pharmaceuticals Inc have a product recall in the last two years?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Agios Pharmaceuticals Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose parental leave metrics?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Agios Pharmaceuticals Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose its waste policy?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc report according to TCFD requirements?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose energy use targets?
Sign up for free to unlockDoes Agios Pharmaceuticals Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Agios Pharmaceuticals Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Agios Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.